

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/48, 39/395, G01N 33/15, 33/543, 33/554, 33/577	A1	(11) International Publication Number: WO 95/13821 (43) International Publication Date: 26 May 1995 (26.05.95)
(21) International Application Number: PCT/US94/13299 (22) International Filing Date: 18 November 1994 (18.11.94) (30) Priority Data: 08/155,435 19 November 1993 (19.11.93) US (71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Center for Technology Transfer, Suite 300, 3700 Market Street, Philadelphia, PA 19104-3147 (US). (72) Inventor: LESSEY, Bruce, A.; 520 Pleasant Green Road, Hillsborough, NC 27278 (US). (74) Agents: CALDWELL, John, W. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris, One Liberty Place - 46th floor, Philadelphia, PA 19103 (US).	(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i>	
(54) Title: $\alpha_v\beta_3$ INTEGRIN AS A PREDICTOR OF ENDOMETRIOSIS (57) Abstract Methods of predicting endometriosis comprise obtaining a sample of endometrium selected from menstrual cycle day 20 to 24, identifying the endometrial sample as nulliparous, contacting the endometrium with a monoclonal antibody for β_3 integrin, assaying for β_3 integrin and correlating the absence of β_3 integrin with endometriosis, wherein the endometrium is identified as mild/minimum endometriosis. A method of using monoclonal antibodies to predict endometriosis is also within the scope of the invention. Methods for detecting receptivity of mammalian endometrium to embryo implantation comprising obtaining a sample of the endometrium, contacting the endometrium with a monoclonal antibody for β_3 and detecting β_3 in the endometrium. The invention also provides for methods of diagnosing infertility in a mammal and methods of detecting the window of embryo implantation in endometrium. Methods of <i>in vitro</i> fertilization, methods of preventing embryo implantation and a method of monitoring endometrial maturation are also within the scope of the present invention. The present invention is also directed to contraceptives. Diagnostic kits useful in the practice of the methods of the invention are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo			SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

$\alpha_v\beta_3$ INTEGRIN AS A PREDICTOR OF ENDOMETRIOSIS

REFERENCE TO APPLICATIONS

This application is a continuation in part of application Serial No. 897,706, filed June 12, 1992.

5 REFERENCE TO GOVERNMENT GRANTS

This work was supported in part by research grants from the Biomedical Research Support Grant Program, Division of Research Resources, the National Institutes of Health, grant numbers B.R.S.B. S07-RR-05415-29 and HD30476-1. The
10 United States Government may have certain rights in this invention.

BACKGROUND OF THE INVENTION

Over the past decade, investigators have come to recognize the importance of the extracellular matrix (ECM) in
15 directing the growth, differentiation and function of the overlying epithelium. Getzenberg et al., "The Tissue Matrix: Cell Dynamics and Hormone Action", *Endocrine Rev.* 1990, 11:399. The interaction between cell and extracellular matrix (or substratum) is mediated by several classes of cell
20 adhesion molecules, one of the most important being the integrins. Albelda et al., "Integrins and Other Cell Adhesion Molecules", *FESEB J.* 1990, 4:2868. Buck et al., "Integrin, a Transmembrane Glycoprotein Complex Mediating Cell-Substratum Adhesion", *J. Cell Sci. Suppl.* 1987, 8:231.
25 This diverse family of glycoprotein receptors is expressed on the cell membrane as heterodimeric α and β integrin subunits and is involved in both cell-cell and cell-substratum adhesion. Specific recognition and binding of extracellular

- 2 -

matrix (ECM) components such as fibronectin (FN), laminin (LM) and collagen (Col) transmit information to the cytoskeletal structure, an interaction which may have major roles in promoting hormone responsiveness and genomic activation. Burridge et al., "Focal Adhesions: Transmembrane Junctions Between the Extracellular Matrix and the Cytoskeleton", *Ann. Rev. Cell. Biol.* **1988**, 4:487 and Getzenberg et al. *supra*.

Although extensive information exists about specific integrin proteins, for example, Hemler, M.E. "VLA Proteins in the Integrin Family: Structures, Functions and Their Role on Leukocytes", *Annu. Rev. Immunol.* **1990**, 8:365, little is known concerning the distribution of these receptors in the female reproductive tract. In the uterus, the endometrium, composed of glandular epithelium and associated mesenchyme (stroma), maintains complex temporal and spatial functions in response to the cyclic hormonal milieu. While Tabibzadeh reported that dynamic alterations in integrin expression accompany the other histologic changes that temporally mark the menstrual cycle, Tabibzadeh, S., "Patterns of Expression of Integrin Molecules in Human Endometrium Throughout the Menstrual Cycle", *Hum. Reprod.* **1992**, 7:876, the search for morphological or biochemical markers for uterine receptivity has been unsuccessful to date as reported by Rogers and Murphy, "Uterine Receptivity for Implantation: Human Studies", in *Blastocyst Implantation* **1989**, Yoshinaga, K. ed., Serono Symposia, p. 231. Once such markers are identified, their role in endometrial phenomena including embryo implantation, fertility, contraception and endometrial maturation and receptivity can likely also be identified. Thus, as some integrins appear to meet the criteria for markers of receptivity there is a great need for methods of detecting integrin cell adhesion molecules in endometrium.

Asynchrony between uterine and embryonic development has been suggested as a cause of pregnancy loss, on the basis of a misalignment between endometrial and

- 3 -

embryonic receptivity, see Pope, et al., "Uterine Asynchrony: A cause of Embryonic Loss", *Biol. Reprod.* 1988, 39:999.

The relationship between minimal endometriosis and nulliparity and infertility remains controversial. While
5 many cogent arguments exist to support this association, many clinicians today still do not believe that minimal or mild forms of the disease are detrimental to a couple's fertility. Several studies comparing women with normal endometrium to
10 women with mild or minimal endometriosis have demonstrated a decrease in cycle fecundity, such as success rates in donor programs, IVF, or GIFT, supported by animal models. One reason for this lack of acceptance is the finding of many studies that expectant management yields pregnancy rates as high as most currently used treatments.

15 Of the many mechanisms suggested to explain the decline in cycle fecundity of endometriosis patients, a defect in uterine receptivity has received perhaps the least attention. Fedele reported specific changes in the native endometrium in women with severe endometriosis, Fedele, L.,
20 et al., "Structural and Ultrastructural Defects in Preovulatory Endometrium of Normo-Ovulating Infertile Women with Minimal or Mild Endometriosis", *Fertil. Steril.* 1990, 53:989. Yovich suggested that severe endometriosis was associated with a defect in implantation, based on IVF-ET
25 experience, see Yovich et al., "Hormonal Profiles and Embryo Quality in Women with Severe Endometriosis Treated by In Vitro Fertilization and Embryo Transfer", *Fertil. Steril.* 1988, 50:308. There is data from studies in the rabbit to suggest that implantation is adversely affected by surgically
30 induced endometriosis, and that the effect is mediated by the peritoneal fluid, see Hahn et al., "Experimental Evidence for Failure to Implant as a Mechanism of Infertility Associated with Endometriosis", *Am. J. Obstet. Gynecol.* 1986, 155:1109.

Endometriosis is a disorder that affects an
35 estimated 2-5% of the general fertile female population, yet its prevalence in infertile women approaches 30-50%, Peterson et al., "Laparoscopy of the infertile Patient", *Obstet.*

- 4 -

Gynecol. 1970, 36:667. While many affected women may have no symptoms, others suffer from dysmenorrhea (painful, difficult menstruation), dyspareunia (pain during intercourse), menstrual disturbances and infertility. That mild or minimal endometriosis is associated with infertility has been suggested by numerous studies, Hasson H.M., "Incidence of Endometriosis in Diagnostic Laparoscopy", *J. Reprod. Med.* 1976, 16:135 and has been recently reviewed, Bancroft, et al., "Minimal/Mild Endometriosis and Infertility. A Review", *Br. J. Obstet. Gynaecol.* 1989, 96:454. The mechanism by which minimal endometriosis causes infertility remains uncertain. Adverse effects on folliculogenesis, ovulation, ovum transport, fertilization, sperm quality, embryos, luteal phase function, and an increase in spontaneous abortion rates have all been postulated. These effects may be mediated by elaboration of peritoneal factors such as prostaglandins, cytokines, and growth factors; activation of peritoneal macrophages, or alterations in immune function such as decreased activity of natural killer cells. Kurzrock et al., "LIF: Not Just a Leukemia Inhibitory Factor", *Endo. Rev.* 1990, 12:208. A few authors have suggested that uterine receptivity to the embryo might be primarily affected by the presence of endometriosis, Muscato, et al., "Sperm Phagocytosis by Human Peritoneal Macrophages: A Possible Cause of Infertility in Endometriosis", *Am. J. Obstet. Gynecol.* 1982, 144:503 and Yovich et al., *supra*; and limited data from surgically induced endometriosis in animal models support this hypothesis, Hahn, et al., *supra*. Further, structural abnormalities have been described in the endometrium of women with endometriosis compared to normal fertile controls, Fedele, et al., *supra*.

Numerous approaches have been investigated to identify women with endometriosis using non-surgical means. Serum markers such as OC-125, (Barbieri, et al. "Evaluation of a Serological Test for the Diagnosis of Endometriosis using a Monoclonal Antibody OC-125", SGI Annual Meeting 1985; March:331P (abstract)) is increased in women with

- 5 -

endometriosis, though the overlap with normal or other disease states severely limits its utility as a diagnostic test, Hornstein, et al., "Menstrual Cyclicity of CA-125 in Patients with Endometriosis", *Fertil. Steril.* 1992, 58:279.

5 Further, given its graduated elevations with severity of disease, OC-125 has little utility in cases of minimal or mild endometriosis. Other modalities such as MRI or ultrasound also have their highest sensitivity in the presence of advanced endometriosis. To date, no method other
10 than laparoscopy has been demonstrated to provide proven efficacy for the diagnosis of minimal or mild stages of endometriosis.

While uterine receptivity remains a poorly understood phenomenon, the initial attachment of embryo to
15 maternal uterine lining is thought to be a critical step in the implantation process. A window of implantation has been defined by descriptive studies from the 1950s as well more recent studies using advanced reproductive technologies, Hertig et al., 1956 and Navot et al., 1992. The presence of
20 an integrin cell adhesion molecule that reliably appears on the endometrial epithelial cells after day 19 of the normal menstrual cycle, corresponds to this putative time of implantation, Lessey, et al., "Integrin Adhesion Molecules in the Human Endometrium", *J. Clin. Invest.* 1992, 90:188. The
25 expression of this integrin, the $\alpha_v\beta_3$ vitronectin receptor, is delayed in women with maturational delay of the endometrium, (where endometrial histology is delayed or retarded because of inadequate hormone levels or decreased response to existing levels of hormones) as well. As it has
30 been suggested by some that infertility due to endometriosis may reflect a defect in uterine receptivity, it is of interest to investigate the expression of this protein in the endometria of women with infertility. The use of integrins as diagnostic tools to investigate uterine receptivity proves
35 to be of significant value in identifying affected individuals and assist in understanding the etiology of infertility associated with mild forms endometriosis.

- 6 -

SUMMARY OF THE INVENTION

The present invention is directed to methods of predicting endometriosis. Methods of using monoclonal antibodies to β_3 integrin are also within the scope of the invention.

The methods of predicting endometriosis comprise obtaining a sample of endometrium selected from menstrual cycle day 20 to 24, identifying the endometrial sample as nulliparous, contacting the sample with a monoclonal antibody specific for β_3 integrin, assaying for β_3 integrin in the sample, and correlating the absence of β_3 integrin with endometriosis, wherein the endometrium is identified as mild/minimal endometriosis. The present invention is also useful in predicting endometriosis in the general infertile female population.

The methods of using monoclonal antibodies to β_3 integrin to predict endometriosis comprise obtaining a sample of endometrium selected from menstrual cycle day 20 to 24, contacting the sample with a monoclonal antibody specific for β_3 integrin, assaying for β_3 in the sample, correlating the absence of β_3 with endometriosis, wherein the endometrium is identified as nulliparous or having mild/minimal endometriosis.

The present invention is directed to methods of detecting receptivity of endometrium to embryo implantation by detecting the β_3 subunit of the α_v/β_3 integrin in endometrium with a monoclonal antibody.

Methods of diagnosing fertility and methods of monitoring endometrial maturation in a mammal are also provided by monitoring the appearance of the β_3 subunit of integrin in endometrium from a plurality of stages of the endometrial cycle. This is preferably done with a monoclonal antibody.

The present invention also provides methods of detecting the optimal window of embryo implantation in the endometrium by detecting the β_3 subunit of integrin in an endometrial sample, preferably with a monoclonal antibody.

- 7 -

Further aspects of the invention include methods of preventing embryo implantation by contacting the β_3 subunit of integrin in the endometrium with neutralizing Fab antibody fragments to β_3 . Methods of *in vitro* fertilization are also
5 embodiments of the invention. These comprise detecting the β_3 subunit of integrin in an endometrial sample, fertilizing an egg *in vitro*, and introducing the zygote into the uterus having endometrial tissue expressing the β_3 subunit.

Contraceptive and diagnostic kits are also
10 contemplated hereby.

These and other aspects of the invention will become more apparent from the following detailed description when taken in conjunction with the following figures.

BRIEF DESCRIPTION OF THE DRAWINGS

15 Figure 1 depicts immunoperoxidase staining of normal endometrium. The photomicrographs depict the pattern of distribution for six different integrins that do not appear to change throughout the menstrual cycle. Dark areas represent positive staining, light areas represent absence of
20 stain (absence of specific integrin subunit). Immunohistochemical staining of the collagen/laminin receptor subunits: α_2 (A), α_3 (B), α_6 (C), and β_4 (D) shows prominent staining of epithelium (\leftarrow) and microvessels (\leftarrow) without significant stromal staining (*) for α_2 , α_3 , and β_4 . Note
25 basolateral staining α_6 and basal staining for β_4 . Staining for fibronectin receptor subunits α_4 (E) is not present in the proliferative stage, α_5 (F) shows predominant mesenchyme staining (*) with decreased epithelial staining (\leftarrow). The immunoreactions (areas of dark staining) were developed by
30 avidin-biotin-peroxidase complex using diaminobenzadine as a chromogen. For greater sensitivity, no counterstain was applied.

Magnification: 125X.

Figure 2 shows photomicrographs of the
35 immunohistochemical staining for the integrin subunit α_1 in proliferative vs. secretory endometrium. The staining in the

- 8 -

glandular epithelium (\leftarrow) was largely absent in the proliferative phase (A), and pronounced in all sections after menstrual cycle day 14 (B; day 20 endometrium). The microvasculature (\leftarrow) staining was also pronounced, and did
5 not change throughout the menstrual cycle. The staining noted in secretory endometrial glands was significantly higher than that of background (C). Magnification: 125X.

Figure 3 exhibits immunostaining of α_v and β_3 (the two pairing subunits of the vitronectin receptor integrin) in
10 proliferative phase vs. secretory phase endometrium. The staining intensity of α_v in the proliferative phase (A) was judged as "+" for the stromal cells (*) and "+" for glandular α_v (\leftarrow). Immunostaining for α_v in day 22 endometrium (B) demonstrates a significant increase in glandular staining
15 (example of "++" staining intensity). Likewise, the staining for β_3 was absent in proliferative epithelium (C; \leftarrow) and was notably increased in this day 22 secretory endometrium (D). Magnification: 125X.

Figure 4 shows relative intensity of staining for
20 the epithelial α_v and β_3 subunits in 35 endometrial samples throughout the menstrual cycle. The pattern of expression for α_v is shown in A, shows a gradual increase in staining throughout the menstrual cycle. In contrast, the pattern for β_3 in B, shows a more abrupt rise in this integrin subunit
25 around day 20 of the menstrual cycle. Samples were staged according to the last menstrual cycle. Sections were assigned a score of 0 (-; negative), 1 (\pm ; weak), 2 (+; moderate) or 3 (+++; strong), by a blinded observer, and confirmed by a second observer.

30 Figure 5 depicts staining intensity of epithelial β_3 in 12 infertility patients with delayed endometrial maturation. Endometrium was collected from women undergoing evaluation for infertility. The biopsies were separated into two groups based on the correlation between histologic
35 criteria and the menstrual cycle dating based on the time of ovulation and/or the subsequent menstrual period. Patients with endometrial biopsies 3 or more days "out of phase" (OOP

- 9 -

group) were compared with 25 endometrial biopsies that were "in phase" (Normal) and shown in A. Sections were assigned a score of 0 (-; negative), 1 (\pm ; weak), 2 (+; moderate) or 3 (++; strong), based on the intensity of epithelial β_3 staining. Examples of immunohistochemical staining of an "out of phase" biopsy (B) and a normal "in phase" sample (C) is included to contrast the epithelial β_3 staining in each group. Magnification: 400X.

Figure 6 exhibits immunoblot analysis of proliferative and secretory endometrium, stained for the β_3 subunit. (A) Immunoblot of platelet extract (lane 1) compared with 2 samples from the early and mid proliferative phase (lanes 2,3) and from the luteal phase (lane 4 and 5; days 23 and 26, respectively) demonstrates a band at approximately 95 kD molecular weight, corresponding to β_3 . Samples of endometrium were partially digested with collagenase and the glandular elements obtained (B) using a modification of the methods of Satyaswaroop et al., "Isolation and Culture of Human Endometrial Glands", *J. Clin. Endocr. Metab.* 1979, 48:639. The glands appear as hollow structures free from surrounding stroma. Immunofluorescence of samples from lanes 3 and 4 (C and D, respectively) corresponds to the absence or presence of the 95 kD band in A. Magnification: 400X.

Figure 7 is a scattergram showing the immunohistochemical staining for the β_3 integrin subunit in endometrial samples from day 1 to 28 of the cycle. All samples had known endometrial dating, and none were out of phase, histologically.

Figure 8 displays immunostaining for the β_3 subunit of the $\alpha_v\beta_3$ vitronectin receptor. Endometrial epithelial cells (arrowheads) underwent alterations in β_3 expression throughout the menstrual cycle. Samples were obtained from the proliferative phase (A), early secretory phase (B; day 18), and from the mid secretory phase (C; day 22). An endometrial biopsy from a patient with mild endometriosis (D) had no epithelial staining for β_3 , despite being judged

- 10 -

"normal, in phase day 22-23" by histologic criteria. The immunoreactions (areas of brown staining) were developed by the avidin-biotin-peroxidase complex using diaminobenzadine as a chromagen. Vascular elements (asterisks) stained positive for the β_3 subunit in all samples. For better contrast, the sections were counterstained with methyl green. Green staining signifies the absence of β_3 expression. The patterns of staining in A and B correspond to HSCOREs of 0 and in "C" to an HSCORE of 2.6. Magnification: 200X.

Figure 9 is a comparison of immunostaining results for endometrial β_3 integrin in normal fertile controls (Control; n = 20), infertile women with endometriosis and prior parity (Parous; n = 28) and nulliparous infertile women with endometriosis (Nulliparous; n = 76). The unpaired t test compares the mean of two groups and determines the likelihood of the observed difference occurring by chance; the chance is reported as a p value. Using the unpaired t test, the overall HSCORE was significantly lower in the latter group compared with either of the other two. HSCORE was calculated as described.

Figure 10 displays the distribution of the α_4 and β_3 integrin subunits during the normal menstrual cycle. Note the co-expression of both subunits corresponds to the putative window of implantation, postovulatory days 6-9.

DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention is directed to methods of predicting endometriosis. Methods of using monoclonal antibodies to β_3 integrin are also within the scope of the invention.

The methods of predicting endometriosis comprise obtaining a sample of endometrium selected from menstrual cycle day 20 to 24, identifying the endometrial sample as nulliparous, contacting the sample with a monoclonal antibody specific for β_3 integrin, assaying for β_3 integrin in the sample, and correlating the absence of β_3 integrin with endometriosis, wherein the endometrium is identified as

- 11 -

mild/minimal endometriosis. The sample of endometrium is preferably selected from menstrual cycle days 20 to 24, more preferably menstrual cycle days 20 to 23, even more preferably menstrual cycle day 22. Cycle days 20-24

5 correspond to post-ovulatory days 6-10. The present invention is also useful in predicting endometriosis in the general infertile female population.

The methods of using monoclonal antibodies to β_3 integrin to predict endometriosis comprise obtaining a sample
10 of endometrium, contacting the sample with a monoclonal antibody specific for β_3 integrin, assaying for β_3 in the sample, correlating the absence of β_3 with endometriosis, wherein the endometrium is identified as nulliparous or having mild/minimal endometriosis.

15 The present invention is directed to methods of detecting receptivity of mammalian endometrium including obtaining a sample of endometrium, contacting the sample with a monoclonal antibody for the β_3 subunit of integrin and detecting the β_3 subunit.

20 For purposes of the present invention, the β_3 subunit may be β_3 alone or β_3 in combination with another integrin subunit, α_v for example.

As used herein integrin is defined as a diverse class of glycoprotein receptors expressed on the cell
25 membrane. Integrins are cell adhesion molecules of the immunoglobulin superfamily. Integrins are composed of heterodimeric α and β subunits and are involved in cell - cell and cell - extracellular matrix adhesion. The integrin family is a broadly distributed group of receptors composed
30 of non-covalently associated α/β heterodimer pairs that mediate leukocyte - leukocyte and leukocyte - endothelial cell adhesion, as well as cellular interactions with extracellular matrix components such as collagen, laminin, fibrinogen and fibronectin, and cell-cell interaction in
35 organized tissues.

While integrins are found on virtually all cell types (the exception being red blood cells), expression of

- 12 -

integrin subunits varies from cell type to cell type. In human uterine endometrium, as determined herein, glandular epithelial cells express primarily α_2 , α_3 , and α_6 integrin subunits, which are collagen laminin receptors. Stromal cells express predominantly α_5 , a fibronectin receptor. The presence of α_1 on glandular epithelial cells is menstrual cycle specific, found only during the secretory phase. Expression of both subunits of the vitronectin receptor, α_v/β_3 , also undergoes menstrual cycle specific changes on endometrial epithelial cells. The expression of α_v increases throughout the menstrual cycle while the β_3 subunit appears abruptly on menstrual cycle day 20 on luminal and glandular epithelial cells. α_4 expression was also found to turn off on day 23. Assaying for the expression of β_3 with monoclonal antibody SSA6 revealed β_3 expression from day 20 onward into the cycle. α_4 expression begins on day 14 and is no longer expressed after day 23, as determined by assaying for α_4 with monoclonal antibody B5G10, provided by Martin Hemler, Dana Farber Cancer Center, Boston, MA. Further, in accordance with the present invention, it has been discovered that α_4 and β_3 expression overlap between days 19-21, the window of implantation.

As a result, as seen in Figure 10, integrins define the window of implantation in the fertile, reproductive aged female. These cell adhesion molecules are dynamically regulated around the time of implantation and serve as excellent marker proteins for this time of the menstrual cycle. As shown in Figure 10, the co-expression of α_4 and β_3 (representing two different integrin species) coincide precisely with the known window of implantation (post ovulatory days 6-9, based on the work of Hertig et al., 1956 and Navot et al., 1992). In contrast to the β_3 integrin which appears to be disrupted in numerous females with infertility, the α_4 integrin does not. While the process of implantation will likely involve many different proteins or factors, such as the co-expression of two different integrins as α_4 and β_3 , the loss of a single entity such as β_3 appears

- 13 -

to be sufficient for the loss of fertility seen in these patients with endometriosis.

The present invention is directed to endometrium of the uterus of a mammal. The uterine wall is largely smooth muscle or myometrium. The endometrium, a glandular layer of variable thickness extremely sensitive to the hormones estrogen/progesterone, lines the myometrium. The endometrium is composed of several functional layers. The layer nearest the myometrium is termed the basalis layer, and the layer closer to the surface known as the functionalis. This tissue is made of epithelial cells, stromal (or mesenchymal) cells and endometrial leukocytes. The epithelial cells are either glandular (forming glands beneath the surface of the endometrium) or luminal (lining the surface of the endometrium). These different types of epithelium serve different purposes and staining patterns for different marker proteins are not always the same between glandular and luminal. It is the luminal surface that would encounter the human embryo first and is thought to be involved in initial attachment. The endometrium of premenopausal girls and postmenopausal women is atrophic due to the lack of the hormones, estrogen and progesterone. In the reproductive-aged woman, the endometrium undergoes cyclic developmental changes based on the ovarian cycle of hormone release. The first day of menstruation is the first day of the cycle; menstruation is generally completed by day 5. The endometrial growth then resumes under the influence of estrogen and progresses through the day 14, proliferative phase, and on to about day 28. From day 14 to day 28 the endometrium also shows signs of increased gland growth and secretion, secretory phase, due largely to the influence of progesterone. During the follicular phase, while follicles are growing in the ovary, and estrogen is the dominant hormone, the endometrium grows thicker. With ovulation (typically day 14 of a 28 day cycle) the women is exposed to estrogen plus progesterone. This is called the secretory or luteal phase, and is noted for a stereotypic series of histologic changes that proceeds as the

- 14 -

cycle continues. These histologic changes are used by pathologists to date the endometrium, a process that remains controversial despite its use for the past 40 years. There have been no reliable immunohistochemical markers reported
5 that have proven utility in dating the endometrium.

Luteal phase dysfunction (LPD) is a term for developmental delay of the endometrium. It is a known cause of infertility, because of dyssynchrony between the fertilized egg and the endometrium. If an embryo is ready to
10 attach but the endometrium is delayed, then pregnancy is not likely to occur. The causes for LPD include inadequate hormonal output by the ovary, and may implicate defective signaling from higher centers such as inadequate gonadotropic hormone output from the pituitary or hypothalamus. LPD is a
15 known cause of infertility and spontaneous abortion and can be corrected with hormone augmentation.

Embryo implantation stages include: apposition - when the epithelial cells of the embryo attach to the outer (luminal) epithelial cells of the maternal endometrial
20 surface; adhesion; and invasion of trophoblast into the underlying stroma where it established itself and begins to grow. Contact with maternal blood vessels is made to gain nutrients and oxygenated blood and to rid itself of waste products during the invasion stage. The stage of development
25 that the embryo reaches at the time of implantation is the blastocyst stage, which occurs at the same time as hatching. There is evidence that hatching is required before implantation occurs, perhaps because the embryo must have its epithelial cells exposed (out of the zona pellucida shell) to
30 interact with the maternal cell layers. As set forth herein, this interaction occurs via integrins.

For purposes of the invention, endometriosis is defined as an ectopic occurrence of endometrial tissue, frequently forming cysts containing altered red blood cells.
35 Stages of endometriosis have been established by the American Fertility Society, AFS. American Fertility Society: Revised American Fertility Society Classification of Endometriosis:

- 15 -

1985. Fertil Steril 1985; 43:351-352. The AFS defines stage I endometriosis as mild and stage II endometriosis as minimal.

As set forth in the present invention, infertility is defined as diminished or absent fertility such that a female mammal has adequate anatomical structures and equivocal function with possibility of pregnancy that may not proceed to term. Nulliparous includes, and is not limited to, endometrium from a female mammal who has not borne offspring. Nulliparous includes females who have conceived offspring and have not carried beyond 20 weeks gestation, instead having spontaneous abortions. Parous is defined in accordance with the present invention as having borne young, alive or dead, after a gestation of 20 weeks and a weight of 500 grams, for humans. Appropriate lengths of gestation and weight are applicable to other mammals such that they would be comparable to those set forth for humans.

For purposes of the current invention, mammals include, but are not limited to the Order Rodentia, such as mice; Order Logomorpha, such as rabbits; more particularly the Order Carnivora, including Felines (cats) and Canines (dogs); even more particularly the Order Artiodactyla, Bovines (cows) and Suines (pigs); and the Order Perissodactyla, including Equines (horses); and most particularly the Order Primates, Ceboids and Simioids (monkeys) and Anthropoids (humans and apes). The mammals of most preferred embodiments are humans. Monoclonal antibodies useful in the practice of the invention include any monoclonal antibodies having an affinity to or binding to the β_3 subunit of integrin. An example of such a monoclonal antibody is SSA6. Monoclonal antibody SSA6 may be produced as described by Bennett et al., PNAS 1983, 80:2417 and Brass et al., J. Biol. Chem. 1985, 260:7876.

Monoclonal antibodies which recognize β_3 combined with another integrin subunit may also be used. One such monoclonal antibody is 23C6, which may be prepared according to the method of Davies et al., J. Cell Biol. 1989, 109:1817.

- 16 -

Immunostaining with monoclonal antibodies such as 23C6 (specific to the intact α_v/β_3 integrin, i.e. the vitronectin receptor) produces the identical pattern as SSA6 which only measures the β_3 subunit. This demonstrates that while α_v specific antibodies measure all the α_v containing integrins, antibodies which recognize the intact α_v/β_3 integrin or the β_3 subunit can be used to study this integrin (the α_v/β_3 "vitronectin receptor").

Other monoclonal antibodies can be used. The preparation of monoclonal antibodies is known to those in the art. Particularly, the method of Kohler and Milstein, *Nature* 1975, 256:495 may be used to produce monoclonal antibodies for use in the invention.

Methods of obtaining endometrial tissue samples for analysis, include any surgical and nonsurgical technique known in the art. Surgical methods include, but are not limited to biopsy, dilation and curettage. Nonsurgical methods include, but are not limited to, uterine washings and uterine brushings with immunocytochemical evaluation.

Methods of detecting β_3 in the endometrium include all methods of identifying glycoproteins known in the art. These methods include, but are not limited to, immunohistochemistry techniques such as immunoblotting or Western blotting, immunoperoxidase staining, fluorescein labeling, diaminobenzadine and biotinylation.

Generally, immunohistochemistry involves staining cryosectioned tissue samples. As used herein, endometrium samples may be cryosectioned to about 4-8 μ thick. Endometrium is contacted with primary antibody, such as SSA6, followed by contact with secondary antibody, such as biotinylated goat anti-mouse antibody. Endometrium is then incubated in avidin-conjugated horseradish peroxidase macromolecular complex followed by chromagen incubation, such as diaminobenzadine. Fluorescein may then be added to observe integrin distribution.

Immunoblotting involves the analysis of protein, here integrin, on sodium dodecylsulfate-polyacrylamide gel

- 17 -

electrophoresis SDS-PAGE. The gel is run under nonreducing conditions and the samples are transferred to a nitrocellulose membrane for example. The membrane is incubated in media containing primary antibody, such as SSA6.

- 5 The filter is developed using a secondary antibody, such as alkaline phosphatase-conjugated goat anti-mouse antibody.

The methods of the present invention directed to predicting endometriosis comprise obtaining a sample of endometrium, identifying the sample of endometrium as
10 nulliparous, contacting the sample with a monoclonal antibody specific for β_3 integrin, assaying for β_3 integrin in the sample, and correlating the absence of β_3 integrin with endometriosis, wherein endometriosis is mild/minimal endometriosis.

- 15 Methods of using monoclonal antibodies to β_3 integrin to predict endometriosis are also within the scope of the invention and comprise obtaining a sample of endometrium, identifying the sample of endometrium as nulliparous, contacting the sample with a monoclonal antibody
20 specific for β_3 integrin, assaying for β_3 integrin in the sample, correlating the absence of β_3 integrin with endometriosis, wherein the endometrium is identified as mild/minimal endometriosis.

- The methods of diagnosing infertility and for
25 detecting the window for embryo implantation in the endometrium of a mammal are also within the scope of the invention. As provided herein, the β_3 subunit of integrin appears at day 20 of the menstrual cycle. It is also provided herein that α_v/β_3 on endometrial epithelium binds
30 fibronectin, vitronectin and osteopontin. These molecules may provide a bridge between the α_v/β_3 integrin of the endometrium and the embryo. Further, patients with luteal phase dysfunction have delayed endometrial maturation, infertility and negative staining for β_3 on days 20 through
35 24. Thus, the optimal time for fertility may be determined by repetitively testing endometrial samples at a plurality of stages in the menstrual cycle. As such, screening for β_3

- 18 -

provides a method of diagnosing infertility and for detecting the window of embryo implantation in the endometrium. The window of implantation is that time when the endometrium of the uterus is available for embryo implantation. This window
5 is preferably from day 19 to day 23, and more preferably day 20 of the human menstrual cycle, marked by the expression of α_v/β_3 integrin.

Similar cycles are known for other mammals - it is within the ordinary skill in the art to adopt the foregoing
10 methodology to such cycles.

The present invention is also directed to methods of *in vitro* fertilization. Once the β_3 subunit of integrin is detected in an animal selected for pregnancy, a fertilizable egg (or eggs) from the same or different animal
15 could be replaced into the uterus to establish pregnancy. The egg and appropriate sperm are combined to produce a zygote *in vitro*. For purposes of the invention, *in vitro* fertilization may take place in a petri dish, in a test tube or the like. In addition, *in vitro* fertilization may also
20 refer to independently adding eggs and sperm to the fallopian tubes such that the zygote is formed therein. In any event, the zygote is introduced to the uterus of the animal selected for pregnancy and monitored for implantation into the endometrium of the uterine wall.

25 Alternatively, the invention is directed to methods of preventing embryo implantation. Such may be carried out by contacting the endometrium with a neutralizing Fab fragment specific for β_3 . For purposes of the present invention, Fab fragments from monoclonal antibodies which
30 bind β_3 are within the scope of the invention. Fab fragments include, but are not limited to, Fab fragments from monoclonal antibodies SSA6 and 23C6. The Fab fragment may remain *in vivo* for a therapeutically effective time to prevent embryo implantation. The Fab fragment comprises the
35 ligand binding portion of a monoclonal antibody for β_3 , i.e. the binding site for β_3 . A neutralized Fab fragment is used

- 19 -

in place of a typical monoclonal antibody to reduce the possibility of an inflammatory reaction.

Contraception is a further embodiment of the invention. A contraceptive may include a therapeutically effective amount of neutralizing Fab fragment monoclonal antibodies specific for β_3 integrin in a pharmaceutically acceptable carrier, preferably adapted for intrauterine application. The Fab fragment may be from a monoclonal antibody which recognizes β_3 , such as and not limited to SSA6. The contraceptive may include β_3 in combination with other integrin subunits, such as and not limited to α_v for example. In the case of $\alpha_v\beta_3$, the Fab may be from monoclonal antibody 23C6.

Compounds which specifically block binding of the embryo to this $\alpha_v\beta_3$ receptor are also included within the scope of the present invention. Examples include peptides containing the amino acid sequence arginine - glycine - aspartic acid, RGD (Pierschbacher et al., "Synthetic Peptide with Cell Attachment Activity of Fibronectin", *PNAS* 1983, 80:1224) which is the active binding site for the vitronectin receptor. This sequence has been reported to block attachment of pregnancy derived cells (trophoblast) *in vitro* by researchers, Kao et al., "The Human Villous Cytotrophoblast: Interactions with Extracellular Matrix Proteins, Endocrine Function, and Cytoplasmic Differentiation in the Absence of Syncytium Formation", *Development* 1988, 130:693. Thus, a contraceptive containing the sequence RGD may be administered locally to prevent embryo implantation.

Pharmaceutically acceptable carriers include, and are not limited to, vaginal suppositories, intrauterine devices (IUD), gels such as slow release formulation, for example, depo forms of hormones - microcrystals injected and slowly released into the systemic circulation or delivered in silastic tubing. Contraceptive formulations would be administered in about 10 $\mu\text{g/ml}$.

Methods of monitoring endometrial maturation is also within the scope of the present invention. The

- 20 -

endometrium may be monitored for embryo receptivity, embryo implantation, infertility, endometrial replenishment and ovulation.

Diagnostic kits are also within the scope of this invention. Such kits include monoclonal antibodies to rapidly detect β_3 in solution; an absorbant detection device which contains pre-absorbed antibody against β_3 and to which uterine washings can be applied; a developer to make β_3 visible when present.

Compounds which prevent β_3 expression are also included within scope of present invention. Although the regulatory signal for the induction of the endometrial integrin on day 19 to 20 is not yet secured, as a result of the present invention, peritoneal fluid is now known to contain bioactive agents which appear to be related to defective integrin expression in women with infertility and endometriosis. Bioactive components with an abnormal peritoneal milieu may lead to a breakdown in the paracrine crosstalk between endometrial cells within the uterus. Candidates include interleukin-1 β receptor antagonist, elevated in women with minimal and mild endometriosis and recently demonstrated to interfere with implantation in a rodent model, Simon, C., et al., Annual Meeting of the American Fertility Society, Montreal, S2-Abst O-3, 1993. Open or unobstructed fallopian tube may be a prerequisite to endometriosis-mediated effects of endometrial β_3 integrin.

In accordance with the present invention, the hydrosalpinx fluid is herein identified as a potential candidate for causing endometrial defects. The methods of the present invention determined that over 50% of women with distal occlusion of the fallopian tube, which causes tubal fluid accumulation, were found to have a loss of the $\alpha_v\beta_3$ integrin during the time of implantation. Three women who were β_3 negative had complete correction of the defect of integrin expression. These three women underwent endometrial biopsy before and after the hydrosalpinx was surgically removed. This suggests that fluid from the tube, which

- 21 -

accumulates and is allowed to empty back into the uterus causes a dysfunction in the endometrium, resulting in infertility. This is consistent with recent reports showing a decrease in uterine receptivity in women with hydrosalpinx
5 compared to women without hydrosalpinx entering an IVF-in vitro fertilization clinic.

The present invention is directed to a method of treating a mammal having endometriosis comprising screening a mammal suspected of having endometriosis for the presence of
10 hydrosalpinx fluid and inactivating said fluid. The step of inactivating the hydrosalpinx fluid includes, and is not limited to, removing the fluid or contacting antibodies to the fluid. Antibodies may include monoclonal, polyclonal, chimeric antibodies and Fab fragments. Alternatively,
15 screening for factors which may be isolated from hydrosalpinx fluid and inactivating said factor is contemplated by the present invention.

The present is also directed to preventing embryo implantation by contacting fallopian tubes or the uterus with
20 hydrosalpinx fluid or hydrosalpinx fluid factors. Hydrosalpinx may remain *in vivo* for a therapeutically effective time to prevent embryo implantation.

Contraception is a further embodiment of the invention. A contraceptive may include a therapeutically
25 effective amount of hydrosalpinx fluid, or factors isolated therefrom. A contraceptive may alternatively be introduced together with a pharmaceutically acceptable carrier. The dosage of a contraceptive of the present invention is determined with regard to weight, and clinical condition of
30 the patient. The proportional ratio of active ingredient to carrier will naturally depend on the chemical nature, solubility, and stability of the compounds, as well as the dosage contemplated. Contraceptives of the present invention are preferably adapted for fallopian tube or intrauterine
35 application.

- 22 -

The present invention is further described in the following examples. These examples are not to be construed as limiting the scope of the appended claims.

EXAMPLES**5 Human Samples**

Endometrium was obtained from 35 reproductive age women at the time of hysterectomy. Tissue was obtained from the early proliferative (day 5) through late secretory phase (day 28) and all hysterectomies were performed for benign
10 disease. Endometrial biopsies were performed on women as part of their evaluation for infertility. All patients were cycling normally and none had received hormones for at least 3 months prior to surgery. Dating of the endometrium was assessed according to the criteria of Noyes et al., "Dating
15 the Endometrium", *Fertil. Steril.* 1950, 1:3. Endometrial biopsies were evaluated in the context of timing of ovulation and/or the onset of the next menstrual period. Samples were judged as "out of phase" if histologic dating was delayed by 3 or more days relative to the predicted day of the menstrual
20 cycle. Proliferative endometrium was categorized based on histology and on last menstrual period. Samples were transported on ice to the laboratory and were snap frozen on dry ice and stored at -70°C.

Antibodies

25 Monoclonal antibodies (Mabs) P1H5, P1B5, P1D6 specific to α_2 , α_3 , α_5 subunits, respectively, were acquired from Drs. Elizabeth Wayner and William Carter. Mabs TS2/7 and B-5H10 directed against the α_1 and α_4 subunits, respectively were acquired from Dr. Martin Hemler. GoH3, a
30 specific Mab directed against α_6 was acquired from Dr. Arnoud Sonnenberg. Mab SSA6 specific to the β_3 subunit was acquired from Drs. Joel Bennett and James Hoxie. Mab LM142 against α_v was acquired from Dr. David Cheresh. The β_4 antibody was acquired from Dr. Steven Kennel. The 23C6 antibody which
35 recognizes β_3 attached to α_v was obtained from Michael Horton.

- 23 -

Immunohistochemistry

Immunoperoxidase staining was performed on cryostat sections of endometrium samples from throughout the menstrual cycle. Serial cryosections 4-8 μ thick were placed onto
5 poly-L lysine coated slides, fixed in -20°C acetone for 10 minutes, and stained using Vectastain Elite® ABC kits (Vector Laboratories, Burlingame, CA). Diaminobenzadine (DAB; Sigma Chemical Co., St. Louis, MO.) was used as the chromagen. Primary antibody was placed on cryosections following
10 blocking with 1% bovine serum albumin in PBS, and allowed to bind at room temperature for 1 hour. A phosphate buffered saline (PBS) pH 7.2 to 7.4 rinse was followed by secondary antibody consisting of biotinylated goat anti-mouse antibody for 30 minutes. Following a PBS rinse, the endogenous
15 peroxidases were quenched with a 30 minute incubation with 0.3% H₂O₂ in absolute ethanol, followed by a 30 minute rehydration in PBS. Avidin:biotinylated horseradish peroxidase macromolecular complex (ABC) was then incubated on the sections for 30 minutes before adding diaminobenzadine
20 for 3 minutes to complete the reaction. Some samples were treated with 1:200 dilution of fluorescein-labeled anti-mouse antibodies for 1 hr., for immunofluorescent microscopy. Samples were subsequently washed in PBS and mounted. The resulting staining was evaluated on a Nikon microscope at low
25 (100x) and higher (400X) magnification with or without fluorescence. Staining was judged as absent (-), weak (\pm), moderate (+) or strong (++). Examples of each is presented in Figure 3. Photomicrographs were made using Kodak T-MAX 100 ASA film.

30 Integrin Distribution in Normal Endothelium

The distribution of α_2 , α_3 , α_6 , and β_4 subunits of integrins which recognize primarily collagen (Col) and/or laminin (LM) is shown in Figure 1 A-D. These subunits were present on glandular epithelium (\leftarrow) throughout the menstrual
35 cycle. Their distribution within the endometrium was typical of that seen for most epithelial tissues. The α_2 and α_3

- 24 -

subunits were distributed around the entire circumference of the cells, while the α_6 and β_4 subunits appeared to be localized at the basolateral surface, adjacent to the basement membrane (BM) of the endometrial glands. The expression of these subunits by the mesenchyme (*) was less pronounced. While moderate staining was seen for α_6 on stromal cells (Figure 1C) very little staining was noted for β_4 . The expression of the α_4 and α_5 subunits of integrins known to bind fibronectin (Table 1) was quite restricted.

10 The α_4 subunit was undetectable above background staining (compare Figure 1E with Figure 2C) in either epithelium or mesenchyme. The α_5 subunit (Figure 1F), representative of the classic fibronectin receptor was not seen on the epithelial components, but was strongly expressed in the

15 mesenchyme which is rich in fibronectin.

TABLE 1
DISTRIBUTION OF INTEGRINS BY LIGAND SPECIFICITY

	Ligands	
	Collagen/Laminin	Fibronectin/Vitronectin
20	α_1/β_1	α_4/β_1
Integrin Subunit	α_2/β_1	α_5/β_1
	α_3/β_1	α_v/β_1
	α_6/β_1	α_v/β_3
	α_6/β_4	

25 The intensity of immunostaining for three other subunits of integrins was found to change in a menstrual cycle-dependent manner. Immunostaining for α_1 in the proliferative phase (Figure 2A) was only slightly above background levels (Figure 2C). The intensity of staining

30 increased throughout the secretory phase (Figure 2B). This intense circumferential staining was found on glandular and luminal epithelium on all samples from day 15 to 28. Likewise, α_v was weakly expressed on both the epithelium and

- 25 -

mesenchyme in the proliferative phase (Figure 3A) and staining increased gradually during the secretory phase to the level noted in Figure 3B. During the proliferative phase β_3 staining was only present on the mesenchymal cells (Figure 3C). Increased β_3 staining was apparent on the endometrial epithelium only after day 19 of the menstrual cycle (Figure 3D) on the luminal as well as glandular epithelium, and was also present in a pericellular distribution. In contrast, the basalis layer did not significantly stain for either α_v or β_3 . This changing pattern of epithelial α_v and β_3 throughout the cycle was studied in 35 endometrial samples and is depicted graphically in Figure 4A and 4B.

Collagen/laminin receptors (col/LM) characterized by α_2 , α_3 and α_6 were uniformly expressed throughout the menstrual cycle, see Table 2. The pericellular distribution of α_2 and α_3 subunits was distinctly different from that of α_6 subunit. Characteristic of a laminin receptor, α_6 was concentrated on the basolateral surface. The β_4 subunit which pairs with α_6 , was also found distributed on the basolateral surface of epithelial cells, and its distribution appeared even more restricted to the basal pole. The α_5/β_1 integrin, a major fibronectin receptor, was also uniformly expressed throughout the menstrual cycle. Unlike the collagen and laminin receptors, the distribution of α_5/β_1 was limited to the mesenchyme.

The temporal pattern of distribution of α_v was varied. Immunostaining was first detected prior to the secretory phase with an increase in intensity throughout the cycle. One subunit known to pair with α_v is β_3 . β_3 is not characteristically present on epithelial cells. The abrupt appearance of the β_3 subunit after day 19 suggests that expression of the vitronectin receptor is regulated in human endometrium. The increased epithelial α_v/β_3 staining in normal cycles correlates to an implantation window within the secretory phase. While the physiologic basis for the implantation window has not been previously established, a proposed role of integrins in the initial interaction between

- 26 -

maternal and embryonic cells indicates an endometrial period of receptivity.

TABLE 2
DISTRIBUTION OF INTEGRIN SUBUNITS IN NORMAL ENDOMETRIUM
DURING THE MENSTRUAL CYCLE

Cell Type	Col/LM					FN/VN			
	α_1	α_2	α_3	α_6	β_4	α_4	α_5	α_v	β_3
Epithelial proliferative	○	●	●	● ^b	● ^b	○	○	○	○
10 early secretory	●	●	●	●	●	○	○	*	○
late secretory	●	●	●	●	●	○	○	●	●
Stromal proliferative	○	○	○	●	○	○	●	●	●
early secretory	○	○	○	*	○	○	*	●	●
15 late secretory	*	○	○	●	○	○	*	●	●
b = basolateral distribution of staining ● = + or ++ staining * = ± staining 20 ○ = - staining									

Integrins in Discordant Endometrium

The presence of the epithelial β_3 subunit appeared to be a consistent internal marker of luteal phase maturation, and the timing of β_3 expression correlated with the peri-implantation period or window of embryo implantation. To investigate whether this phenomenon would be useful in the clinical evaluation of endometrial biopsies, immunostaining was performed on luteal phase endometrial samples from cycles which showed evidence of maturational delay. Endometrial biopsies from 25 women who had concordance of menstrual and histologic dating ("Normal" group) were compared to 12 biopsies which were identified as ≥ 3 days out of phase (OOP) based on either the time of ovulatory or the subsequent menses. Samples were immunostained for α_1 , α_v and β_3 subunits. All biopsies were

- 27 -

performed on days 20 to 24 of the menstrual cycle. In all instances, immunostaining for these three antigens was present on endometrial epithelia from the normal group. In biopsies which were delayed by 3 days or more, α_1 and α_v staining was present, but epithelial β_3 staining was absent. The comparison of β_3 staining intensity in the two groups is shown in Figure 5A. Accompanying photomicrographs of β_3 immunostaining from out of phase biopsies (OOP; B) and normal "in phase" biopsies (C) is included, which demonstrates the discrepancy seen in β_3 staining. In subsequent treatment cycles, 2 OOP patients underwent repeat biopsy during a normalized cycle at which time immunostaining for epithelial β_3 was present. This suggests that the lack of β_3 was not an intrinsic defect in the OOP group. Rather, the discordant biopsies which lacked β_3 had not yet established the mid-luteal phenotype of normal day 20 to 24 endometrium.

Cell Harvest and NP-40 Extraction

To further demonstrate that immunohistochemical staining accurately reflected changes in the expression of β_3 subunit on endometrial epithelium, immunoblots (Western blots) were performed on samples of enriched endometrial glandular elements from proliferative and secretory phase. Four samples of endometrium were obtained for the evaluation of the β_3 subunit in proliferative ($n = 2$) and late secretory ($n = 2$) endometrial epithelium. Each sample was placed in Dulbecco's modified Eagle's medium (DMEM; Sigma, St. Louis, MO), supplemented with 10% fetal bovine serum (Flow Laboratories, McLean, VA) glucose (4500 mg/L), Hepes buffer (25 mM), L-glutamine (584 mg/L), and sodium bicarbonate (3.7 gms/L). Endometrium was minced in a plastic petri dish prior to incubation with 6 mg of collagenase (type 1A, 550 units/mg; Sigma, St Louis, MO) for 2 hours at 37°C utilizing modifications of the procedures described by Satyaswaroop et al. in "Isolation and Culture of Human Endometrial Glands", *J. Clin. Endocr. Metab.* 1979, 48:639. The resulting suspension was successively passed through a 250 μ m sieve and

- 28 -

a 38 μ m sieve (Newark Wire Cloth Co, Newark NJ). The course (250 μ m) sieve removed undigested material, while the second retained the glandular elements and excluded the individual stromal and blood cells. After thorough rinsing, the glandular elements were obtained by backwashing with 10 to 20 ml of DMEM. The isolated glandular structures were then transferred to a 1.5 ml microfuge tube and centrifuged 3 times (82 x g) for 2 minutes with intermittent washes with PBS. Membrane extracts were prepared by adding small volumes (100-200 μ l) of 10 mM Tris-acetate, pH 8.0, 0.5% NP-40, 0.5 mM Ca^{2+} (TNC) with 2 mM PMSF (phenyl methyl-sulfonyl fluoride) to the final pellet, pipetted and incubated on ice for 15 minutes. The lysate was centrifuged for 5 minutes at 16,000 x g in a microcentrifuge. The resulting supernatant was called NP-40 extract and was frozen at -70°C until use. A portion of the original, undigested tissue was cryosectioned for immunohistochemical localization of β_3 .

Gel Electrophoresis and Immunoblots

The protein concentration of each NP-40 extract and an extract of platelets (positive control) was determined using technique described by Lowry et al., "Protein Measurement with Folin Phenol Reagent", *J. Biol. Chem.* 1951, 193:265. Samples with equal amounts of protein were added to electrophoresis sample buffer (62.5 mM Tris base, 2% SDS, 10% glycerol, pH 6.8). Samples were analyzed by SDS-PAGE using 6% polyacrylamide gels, using non-reducing conditions described by Laemmli, U.K., "Cleavage of Structural Proteins During Assembly of the Head of Bacteriophage T4", *Nature* 1970, 227:680. The gel was transferred to nitrocellulose using a Biorad transfer apparatus (Biorad, Richmond, CA) and blocked with 4% BSA in PBS with 0.2% Na Azide for 1 hour. After addition of primary antibody (SSA6 supernatant) for 2 hours, the gels were developed using an alkaline phosphatase-conjugated secondary antibody (Promega Corp., Madison, WI) according to methods described by Albelda et

- 29 -

al., "EndoCAM: A Novel Endothelial Cell-Cell Adhesion Molecule", *J. Cell Biol.* 1990, 110:1227.

As shown in Figure 6A, proliferative phase epithelial structures had little to no immunostaining at 95 kD (lanes 2 and 3), compared to the positive control (platelet extract; lane 1) or to samples from the secretory phase (lanes 4 and 5) which showed strong staining for β_3 . The isolated endometrial glands appeared as tubular structures free of surrounding stroma (Fig. 6B). Immunofluorescent staining for β_3 from samples corresponding to lanes 3 and 4 (mid proliferative phase and day 23, respectively) are shown in Fig. 6C and D. Note the absence of glandular staining in the proliferative sample, while both glandular and luminal immunostaining is obvious from the secretory phase. These data confirm that the expression of epithelial β_3 in human endometrium is a cycle specific phenomenon.

Determination of Endometriosis

Patient Selection

Biopsies were obtained from throughout the menstrual cycle from 500 women undergoing evaluation for infertility at the University of Pennsylvania. The biopsies were screened for participation in the study based on criteria including accurate knowledge of menstrual cycle day or "in phase" histology and freedom from menstrual cycle disturbances (anovulation (suspension or cessation of ovulation), perimenopausal state (dysfunctional uterine bleeding), luteal phase defect (histologic evidence of maturational delay of the endometrium), the presence or use of an intrauterine device or endometritis (inflammation of endometrium due to infectious agents or chemical irritation). Patients with endometrial hyperplasia (an increase in the number of cells in endometrium), neoplasia (a pathologic process resulting in formation or growth of abnormal tissue or tumors, benign or malignant), and those on hormonal therapy (including oral contraceptives, estrogen replacement

therapy and progestens) were likewise excluded. Two hundred and sixty eight women were eligible for enrollment in this study, ranging from cycle day 2 through 27. The most common primary diagnosis was endometriosis (41.4%) followed by unexplained infertility (23.5%), see Table 3. Due to the participation criterion of normal "in phase" histology as set forth above, all cases of luteal phase deficiency were excluded.

Table 3
Diagnoses of Subjects with Infertility
Undergoing Endometrial Biopsy (N=268)

	Diagnosis	Number (%)
15	endometriosis	111 (41.4)
	tubal disease	38 (14.2)
	pelvic adhesions	17 (6.3)
	male factor	18 (6.7)
	fibroids	9 (3.4)
20	habitual pregnancy loss	6 (2.2)
	in utero DES exposure	4 (1.5)
	hyperprolactinemia	2 (0.7)
	unexplained infertility	63 (23.5)

Endometrial biopsies of 241 patients were obtained after day 19 (post ovulatory day 6 or greater) based on urinary luteinizing hormone, LH, surge or next menstrual period, a time in the menstrual cycle when epithelial β_3 is expressed, Lessey, et al., *supra*. The remaining patients (n=27) were biopsied prior to day 20 and therefore would not be expected to produce the β_3 integrin. Based on routine infertility workup, including diagnostic laparoscopy which involves the examination of the contents of peritoneum with a laparoscope passed through the abdominal wall, 105 (43.6% of the group) of these women had endometriosis. The 105 women were then considered as the test cases. Twenty women with endometriosis also had documented prior fertility, previously produced young, having parity ≥ 1 , where each women had ≥ 1 prior birth, and had undergone bilateral tubal ligation or had clearly identified male factor infertility, (or infertility of the male partner). These were chosen to serve

- 31 -

as fertile controls. The remaining 116 women (48.1% of the group) were considered the infertile controls.

Immunohistochemistry

Immunoperoxidase staining was performed on the 241
5 samples as described by Lessey, et al., *supra*. Briefly, immunoperoxidase staining was performed on cryostat sections of endometrium throughout the menstrual cycle. Serial cryosections 4-8 μ thick were placed onto poly-L lysine coated slides, fixed in -20°C acetone for 10 minutes, and stained
10 using Vectastain Elite® ABC kits (Vector Laboratories, Burlingame, CA). Diaminobenzadine (DAB; Sigma Chemical Co., St. Louis, MO.) was used as the chromogen. Primary antibody consisting of SSA6 (specific to the β_3 subunit of the vitronectin receptor) was placed on cryosections following
15 blocking with 1% bovine serum albumin in phosphate buffered saline, PBS, and allowed to bind at room temperature for 1 hour. A PBS rinse, pH 7.2 to 7.4, was followed by secondary antibody consisting of biotinylated goat anti-mouse antibody for 30 minutes. Following PBS rinse, the endogenous
20 peroxidases were quenched with a 30 minute incubation with 0.3% H₂O₂ in absolute ethanol, followed by a 30 minute rehydration in PBS. Avidin: biotinylated horseradish peroxidase macromolecular complex (ABC) was then incubated on the sections for 30 minutes before adding diaminobenzadine
25 for 3 minutes to complete the reaction. Samples were subsequently washed in PBS and mounted.

Immunostaining for endometrial β_3 was performed on each of the 268 endometrial biopsies obtained from throughout the menstrual cycle (see Figure 7). Examples of cycle
30 specific expression of β_3 subunit using the immunohistochemical staining are shown in Figure 8A (proliferative), Figure 8B (day 18), Figure 8C (day 22) and a sample from cycle day 23 with negative staining in a patient with endometriosis whose "in phase" biopsy was read as "day
35 22-23" on histologic section (D). As seen in all cases, immunostaining of the vascular endothelium remains present

- 32 -

even in samples with no epithelial staining for this integrin, thus serving as a positive internal control for the immunostaining technique. Based on the distribution of β_3 shown in Figure 7 and the theory that the β_3 subunit is normally expressed in endometrium from day 20 and later, all samples which were histologically dated to cycle day 20 or greater were included for further evaluation (n=241). Cases with known endometriosis (102/241; 43.5%) were compared with infertile controls without endometriosis (116/241; 48.1%) and with 20 fertile controls (20/241; 8.3%). As listed in Table 4, both the endometriosis group and the infertile controls were younger than the fertile controls. The resulting staining was evaluated on a Nikon microscope at low (100X) and higher (400X) magnification. The HSCORE, a semi-quantitative index which estimates both intensity and distribution of positive staining for β_3 integrin, was calculated using the following equation:

$$\text{HSCORE} = \sum P_i (i + 1)$$

where i = intensity of staining with a value of 1, 2, or 3, weak, moderate, or strong, respectively, and P_i is the percentage of stained epithelial cells for each intensity, varying from 0-100%. Low intraobserver values ($r=0.994$; $p=0.00001$) in uterine tissues has been reported using this technique by Budwit-Novotny, D.A., et al., "Immunohistochemical Analyses of Estrogen Receptor in Endometrial Adenocarcinoma Using a Monoclonal Antibody", *Cancer Res.*, 1986 46:5419-5425. Examples of representative HSCOREs reflecting changing levels of staining intensity and distribution is illustrated Figure 8. Photomicrographs were made using Kodak 100 ASA film.

Statistical Analysis

Infertile endometriosis patients were compared to infertile controls without endometriosis and fertile controls. Comparisons were also made between nulliparous

- 33 -

endometriosis patients and parous endometriosis patients on selected characteristics such as age and HSCORE and were performed using the nonparametric Wilcoxon test. Wilcoxon, F., Individual Comparisons by Ranking Methods. *Biometrics* 5 Bull 1945; 1:80-85.

Receiver Operator Characteristic (ROC) analysis was used to determine the optimal cutoff value for HSCORE in women prospectively undergoing laparoscopy. Metz, C. E., Basic Principles of ROC analysis. Sem Nuclear Med 1978; 10 8:283-298. An HSCORE cutoff value was sought as the highest positive predictive value of endometriosis which meant seeking a high specificity at the cost of moderate sensitivity. A high positive predictive value minimizes the number of women who would otherwise undergo unnecessary 15 surgery, using this test as a diagnostic modality for endometriosis. The HSCORE cutoff value was 0.7, which yielded a sensitivity of 38%, specificity of 91%, and a positive predictive value of 86% for the detection of endometriosis.

20 The association between HSCORE and endometriosis was first evaluated by a nonparametric test (Wilcoxon test) and further evaluated by multiple logistic regression in the sample of 241 women whose biopsies were histologically cycle day 20 or greater. As seen in Table 4, the mean HSCORE was 25 significantly lower for the infertile endometriosis group ($p < 0.003$) compared to fertile controls ($p < 0.002$) and the infertile controls without endometriosis ($p < 0.012$; Table 4). Interestingly, the infertile controls without endometriosis also had a borderline lower HSCORE for β_3 , 30 staining than the fertile control group ($p = 0.05$).

- 34 -

Table 4
Demographic and HSCORE Characteristics of Subjects
Whose Endometrial Biopsies Were Histologically
Normal and Cycle Day 20 or Greater

5		Infertile w/ Endometriosis n=105	Infertile w/o Endometriosis Infertile Controls n=116	Fertile Controls n=20
	Characteristic			
10	Age (yr)			
	mean \pm S.D.	34.1 \pm 4.1*	34.5 \pm 4.7**	36.9 \pm 4.9
	Severity			
	AFS score			
	I	40 (38.5%)		
15	II	44 (42.3%)		
	III	15 (14.3%)		
	IV	6 (5.8%)		
	HSCORE			
	Mean \pm S.D.	1.30 (\pm 1.09)*	1.68 (\pm 0.95)**	2.15 \pm (0.66)
20	Median	1.3	1.75	2.05
	Max	3.6	3.4	3.6

* p < 0.003 vs. fertile controls, by Wilcoxon test.

** p < 0.01 vs. fertile controls, by Wilcoxon test.

25 * p < 0.02 vs. fertile controls and p < 0.012 versus
infertile controls without endometriosis, by Wilcoxon test.

** p = 0.05 vs. fertile controls, by Wilcoxon test.

Severity of endometriosis based on AFS
classification appeared to be associated with the presence or
30 absence of the β_3 immunostaining. All 105 patients with
infertility and endometriosis were stratified by severity of
disease. The distribution of cases by AFS severity score is
listed in Table 4. The HSCORE of the two groups based on AFS
severity score, I and II (minimal and mild; n = 84) versus
35 III and IV (moderate and severe; n = 21) demonstrated a
significant difference using a Wilcoxon test (p = 0.0151).
Therefore, defective β_3 expression is specifically associated
with endometriosis stages I and II.

40 Multiple logistic regression using EGRET was used
to evaluate the association between endometriosis and HSCORE,
after adjusting for the effects of age and parity status, and
taking into account the potential interaction of parity

- 35 -

status. Mauritisen, R. EGRET. Statistics and Epidemiology Research Corporation Software. Seattle, WA, 1990.

By multiple logistic analysis, the crude relative risk (RR) and 95% confidence interval (CI) based on a model with only HSCORE as the independent variable and the presence or absence of endometriosis as the dependent (outcome) variable, was 0.6 (0.5-0.8) when calculated for an HSCORE of 0.7 (by ROC analysis). A relative risk (RR) of 1 means there is no effect, that two groups are the same with regard to risk for endometriosis. A RR of 0.6 is highly significant, confidence intervals show the range of confidence of the test. Together, RR and CI define an increased risk of having endometriosis in nulliparous women with a HSCORE of 0.7 or less. The addition of age into the model did not change the result, but there was a statistically significant interaction with parity status ($p = 0.030$). Accordingly, the adjusted RR (95% CI) was 0.6 (0.4-0.9) for nulliparous women compared to 1.2 (0.8-1.8) for parous women. These results indicate that the absence of β_3 (as indicated by HSCORE) in nulliparous women is a statistically significant prediction of endometriosis. Restricting the analysis to women with only minimal and mild disease did not change the result substantially. The adjusted RR (95% CI) in nulliparous women versus 0.5 (0.4-0.8) compared to 1.2 (0.7-1.8) in parous women.

To further examine this relationship between reproductive history and HSCORE, the 105 patients with endometriosis were stratified by parity and compared to the fertile control group (Table 5). The control population was older than the parous and nulliparous endometriosis groups. The HSCORE in the nulliparous endometriosis group was less than that of the parous endometriosis group and the fertile control group ($p < 0.0001$, for each group), but there was no difference between the parous group with endometriosis and the fertile controls ($p = 0.98$). The comparison between these three groups is depicted graphically in Figure 9.

- 36 -

Table 5
Comparison between Nulliparous and Parous Women
with Endometriosis and Normal Fertile Controls

5 Endometriosis Patients n=105				
	Nulliparous n=78	Parous n=27	Fertile Controls n=20	
10	Characteristic			
	Age (yr)			
	mean \pm S.D.	34.1 \pm 4.1 ⁺	34.3 \pm 4.0 ^{**}	36.9 \pm 4.9
	Severity			
	AFS score			
15	I	30 (38.5%)	10 (37.0%)	
	II	33 (42.3%)	11 (40.7%)	
	III	11 (14.1%)	4 (14.8%)	
	IV	4 (5.1%)	2 (7.4%)	
	HSCORE			
20	Mean \pm S.D.	1.03 (\pm 1.04) [*]	2.10 (\pm 0.79) ^{**}	2.15 \pm (0.66)
	Median	0.6	2.1	2.05
	Max	3.6	3.6	3.6

⁺ p < 0.004 vs. fertile controls, by Wilcoxon test.

25 ^{**} p < 0.02 vs. fertile controls, by Wilcoxon test.

^{*} p < 0.0001 vs. parous endometriosis patients and

p < 0.0001 versus fertile controls, by Wilcoxon test.

^{**} p < 0.98 vs. fertile controls, by Wilcoxon test.

The observation that differences in integrin
30 expression correlated with the diagnosis of endometriosis,
prompted the evaluation of the usefulness of this marker in
predicting this disorder in women prospective to the
diagnostic laparoscopy. As a subgroup of the original 241
samples, 89 biopsies were obtained prospectively prior to
35 diagnostic laparoscopy. Chronological dating was established
by urinary luteinizing hormone, LH, surge and/or the onset of
the next menstrual period. Endometrial dating was performed
using the criteria of Noyes et al., "Dating the Endometrium",
Fertil. Steril. 1950, 1:3. All 89 of these women
40 subsequently underwent diagnostic laparoscopy to establish
the presence or absence of endometriosis. The severity of
the disease, when present, was staged according to the

- 37 -

revised American Fertility Society, AFS, criteria set forth in American Fertility Society: Revised American Fertility Society classification of endometriosis, *supra*. The surgeons performing the diagnostic laparoscopies were blinded with regard to the result of the immunohistochemical findings. Likewise the interpretation of the biopsy results (estimation of β_3 expression) was done in a blinded fashion using HSCORE, which estimates both intensity and distribution of positive staining for β_3 integrin. The 0.7 HSCORE value, determined as the optimal cutoff, yielded a sensitivity of 38%, a specificity of 91% and the highest positive predictive value of 86% for the prospective detection of endometriosis. Overall, 50 patients were prospectively found at laparoscopy to have endometriosis at a variety of AFS stages. Negative staining, indicating no β_3 expression, based on ROC analysis, was detected in 22 samples. Of these 22 patients without β_3 staining, 19 were found to have endometriosis. ROC analysis was performed to establish the optimal cutoff value for normal samples. To the best of Applicant's knowledge, the present invention is the first non-surgical test that has been demonstrated to predict the presence of minimal or mild endometriosis.

All patients subsequently found to have endometriosis were not missing the β_3 subunit. The present invention identifies a subgroup of infertility patients with a deficit in β_3 , which characterizes women with defective uterine receptivity. This association between endometriosis and defective β_3 integrin expression may represent the first cycle-specific defect during the putative window of implantation. Detecting the loss of β_3 may signify patients with endometriosis who are most at risk for infertility due to an endometrial factor. While implantation may be the result of a cascade of different molecules, the present invention reveals the loss of a single component may be sufficient to explain a failure of implantation.

The present invention reveals the loss of β_3 , normally expressed at the initiation of the window of

- 38 -

implantation, is associated with women who appear to be the most infertile. Prospective use of this marker protein has demonstrated that the β_3 integrin subunit is a useful test with a high specificity and positive predictive value for the nonsurgical diagnosis of minimal or mild endometriosis. As a potential marker of uterine receptivity that may predict fertility potential, the study of this subgroup of infertility patients allows greater refinement of diagnosing this enigmatic disease.

10 **Determination of Endometriosis in
the Infertile Patient Population**

Biopsies will be obtained from throughout the menstrual cycle from women being evaluated for infertility. Women who are parous and nulliparous will be included in the study. The biopsies will be screened for participation in a study based upon criteria including accurate knowledge of menstrual cycle day or "in phase" histology and freedom from menstrual cycle disturbances (anovulation (suspension or cessation of ovulation), perimenopausal state (dysfunctional uterine bleeding), luteal phase defect (histologic evidence of maturational delay of the endometrium), the presence or use of an intrauterine device or endometritis (inflammation of endometrium due to infectious agents or chemical irritation). Patients with endometrial hyperplasia (an increase in the number of cells in endometrium), neoplasia (a pathologic process resulting in formation or growth of abnormal tissue or tumors, benign or malignant), those on hormonal therapy (including oral contraceptives, estrogen replacement therapy and progestens), and those with luteal phase deficiency will be excluded.

Endometrial biopsies will be obtained after day 19 (post ovulatory day 6 or greater) based on urinary luteinizing hormone, LH, surge or next menstrual period, a time in the menstrual cycle when epithelial β_3 is expressed, Lessey, et al., *supra*. Fertile and infertile controls will also be selected.

- 39 -

Immunoperoxidase staining will be performed on the patient samples as described by Lessey, et al., *supra*. Briefly, immunoperoxidase staining will be performed on cryostat sections of endometrium throughout the menstrual cycle. Serial cryosections 4-8 μ thick will be placed onto poly-L lysine coated slides, fixed in -20°C acetone for 10 minutes, and stained using Vectastain Elite® ABC kits (Vector Laboratories, Burlingame, CA). Diaminobenzadine (DAB; Sigma Chemical Co., St. Louis, MO.) will be used as the chromogen.

10 Primary antibody consisting of SSA6 (specific to the β_3 subunit of the vitronectin receptor) will be placed on cryosections following blocking with 1% bovine serum albumin in phosphate buffered saline, PBS, and allowed to bind at room temperature for 1 hour. A PBS rinse, pH 7.2 to 7.4,

15 will be followed by secondary antibody consisting of biotinylated goat anti-mouse antibody for 30 minutes. Following PBS rinse, the endogenous peroxidases will be quenched with a 30 minute incubation with 0.3% H₂O₂ in absolute ethanol, followed by a 30 minute rehydration in PBS.

20 Avidin: biotinylated horseradish peroxidase macromolecular complex (ABC) will then be incubated on the sections for 30 minutes before adding diaminobenzadine for 3 minutes to complete the reaction. Samples will be subsequently washed in PBS and mounted.

25 The HSCORE and statistical analysis, using Wilcoxon test, ROC analysis, and p values, for infertile females is expected to be similar to that of nulliparous infertile females set forth above. HSCORE cutoff value, sensitivities and specificities values will be determined for the detection

30 of endometriosis in infertile patients. The patients will also be separated as to severity of endometriosis based on AFS classification. EGRET will be used to evaluate the association between endometriosis and HSCORE, after adjusting for the effects of age and parity status, *supra*. Crude

35 relative risk and confidence intervals will be calculated for endometriosis. Overall, it is expected that integrin expression, detected by the absence of β_3 , will correlate

- 40 -

with the diagnosis of endometriosis in infertile females.

Various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such
5 modifications are also intended to fall within the scope of the appended claims.

- 41 -

WHAT IS CLAIMED:

1. A method for predicting endometriosis comprising:
 - a. obtaining a sample of endometrium selected
5 from menstrual cycle day 20 to 24,
 - b. identifying said sample of endometrium as nulliparous,
 - c. contacting said sample with a monoclonal antibody specific for β_3 integrin,
 - 10 d. assaying for β_3 integrin in said sample, and
 - e. correlating the absence of β_3 integrin expression with endometriosis, wherein said endometriosis is mild/minimal endometriosis.
- 15 2. The method of claim 1 wherein said monoclonal antibody is SSA6.
3. The method of claim 1 wherein said β_3 is combined with another integrin subunit.
4. The method of claim 3 wherein said other
20 integrin subunit is α_v .
5. The method of claim 4 wherein said monoclonal antibody is 23C6.
6. The method of claim 1 wherein said β_3 is detected by immunohistochemically staining said sample of
25 endometrium contacted with said monoclonal antibody specific for β_3 .
7. The method of claim 1 wherein said β_3 is detected by immunoblotting β_3 from said sample of endometrium contacted with said monoclonal antibody specific for β_3 .
- 30 8. The method of claim 1 wherein said endometrium is human.

- 42 -

9. A method of using a monoclonal antibody to β_3 integrin to predict endometriosis comprising:
- a. obtaining a sample of endometrium selected from menstrual cycle day 20 to 24,
 - 5 b. identifying said sample of endometrium as nulliparous,
 - c. contacting said sample with a monoclonal antibody specific for β_3 integrin,
 - d. assaying for β_3 integrin in said sample, and
 - 10 e. correlating the absence of β_3 integrin expression with endometriosis, wherein said endometriosis is mild/minimal endometriosis.
10. The method of claim 9 wherein said monoclonal antibody is SSA6.
- 15 11. The method of claim 9 wherein said β_3 is combined with another integrin subunit.
12. The method of claim 11 wherein said other integrin subunit is α_v .
13. The method of claim 12 wherein said monoclonal
20 antibody is 23C6.
14. The method of claim 9 wherein said endometrium is human.
15. The method of claim 9 wherein said β_3 is monitored by immunohistochemically staining said sample of
25 endometrium contacted with said monoclonal antibody specific for β_3 .

- 43 -

16. The method of claim 9 wherein said β_3 is monitored by immunoblotting β_3 from said sample of endometrium contacted with said monoclonal antibody specific for β_3 .

5 17. The method of claim 9 wherein said stages of the menstrual cycle are selected from the group consisting of follicular phase and secretory phase.

10 18. A method of treating a mammal suspected of having endometriosis comprising screening said mammal suspected of having endometriosis for the presence of hydrosalphinx fluid and inactivating said fluid.

15 19. The method of claim 18 wherein inactivating said fluid is selected from the group consisting of removing said fluid and treating said fluid with antibodies to hydrosalphinx fluid.

20 20. A method of preventing embryo implantation comprising contacting fallopian tubes or the uterus with hydrosalphinx fluid.

20 21. A contraceptive comprising a therapeutically effective amount of hydrosalphinx fluid and a pharmaceutically acceptable amount of a carrier.

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E



FIG. 1F



FIG. 2A




FIG. 2B





FIG. 2C






FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D

5/11




FIGURE 4

6/11

FIG. 5A




FIG. 5B




FIG. 5C



SUBSTITUTE SHEET (RULE 26)

FIG. 6C




FIG. 6D




FIG. 6A




FIG. 6B



8/11




FIGURE 7

9/11




FIG. 8A




FIG. 8B

SUBSTITUTE SHEET (RULE 26)




FIG. 8C




FIG. 8D

11/11




FIGURE 9




FIGURE 10
SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/13299

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 35/48, 39/395; G01N 33/15, 33/543, 33/554, 33/577

US CL :424/142.1, 537, 559; 435/7.21; 436/518, 519, 548; 530/388.25

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/142.1, 537, 559; 435/7.21; 436/518, 519, 548; 530/388.25

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, BIOSIS, EMBASE

search terms: endometriosis, integrin, vitronectin receptor, monoclonal antibody, hydrosalphinx, contraceptive

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF CLINICAL INVESTIGATION, Volume 90, issued July 1992, LESSEY, B.A., et al, "Integrin Adhesion Molecules in the Human Endometrium Correlation with the Normal and Abnormal Menstrual Cycle", pages 1-8, see entire document.	1-17

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 FEBRUARY 1995

Date of mailing of the international search report

07 MAR 1995

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/13299

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/13299

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

- I. Claims 1-17, drawn to a method of predicting endometriosis using a monoclonal antibody specific for beta 3 integrin.
- II. Claims 18 and 19, drawn to a method of treating a mammal suspected of having endometriosis by inactivating the hydrosalphinx fluid.
- III. Claims 20 and 21, drawn to a method of preventing embryo implantation and a contraceptive composition of hydrosalphinx fluid.

The claims of Groups I, II and III are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept because the method of Group I requires an antibody which is not required by the methods of Groups II or III, and the methods of Groups II and III require distinct reagents and method steps and have different outcomes.